The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Many cytokines are very useful therapeutic targets in disease
Open accessAbstract
Cytokines are a large family of more than 100 small proteins that function as short-range mediators involved in essentially all biological processes.They have been found to be important rate-limiting signals, and it is now known that blocking some cytokines, e.g., TNF-α, and cytokine receptors, such as human EGFR 1 (HER1) or HER2, yields effective therapeutics that address unmet needs.This Review Series surveys three chronic inflammatory disease areas and two forms of cancer and discusses the important role of cytokines and their receptors in these disease processes.Their role as potential therapeutic targets is also highlighted.Cytokines, low-MW protein mediators that usually act at short range between neighboring cells, have been studied extensively for the past 30 years.These molecules, previously also termed interleukins, interferons, growth factors, and TNFs, among other designations, are involved in essentially every important biological process, from cell proliferation to inflammation, immunity, migration, fibrosis, repair, and angiogenesis (1, 2).As these molecules and their associated receptors provide key signals for important processes, it is not surprising that abnormalities in cytokines, their receptors, and the signaling pathways that they initiate are involved in a wide variety of diseases.Indeed, they have a role in far too many diseases for each to be covered in this Review Series.Rather, representative examples of the cytokines involved in some forms of cancer and immune and inflammatory diseases are discussed.The critical issue in each case is the importance of cytokines as therapeutic targets, and the overwhelming message is that "anti-cytokine medicine" is a rapidly growing field with major pharmaceutical impact. Cytokines: from identification to the clinicThe field of cytokines came of age in the late 1970s with the introduction of molecular biological approaches that resulted first in the cloning of IFNs, initially IFN-β by Tada Taniguchi (3) and IFN-α by both Charles Weissman's group and David Goeddel's colleagues (4, 5).By the mid-1980s, there was a plethora of well-defined cytokines and cytokine receptors that could be unambiguously studied, using molecular tools, such as cDNA probes, and antibodies that had been produced to recognize the pure recombinant proteins.All this was a long way from the 1960s and 1970s, when all researchers had were many uncharacterized bioactivities in cell supernatants termed simply by activity, e.g., lymphocyte-activating factor (6), macrophageactivating factor (7), and leukocyte pyrogen (8).All the tools available by the mid-1980s enabled researchers to assess the expression of cytokines in physiologic and patho-Nonstandard abbreviations used: AD, Alzheimer disease; CML, chronic myelogenous leukemia; COPD, chronic obstructive pulmonary disease; HER, human EGFR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cytokine network in asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36130 · Cited by 982
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001) · Science · doi:10.1126/science.1062960 · Cited by 829
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587
Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology
Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C. A., Tan, J., Duman, R. S., & Flavell, R. A. (2008) · Nature Medicine · doi:10.1038/nm1781 · Cited by 422
Cited by
Tumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
Neutrophil-derived cytokines: facts beyond expression
Tecchio, C., Micheletti, A., & Cassatella, M. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00508 · Cited by 699
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
The Role of the Kinases RIP1 and RIP3 in TNF-Induced Necrosis
Vandenabeele, P., Declercq, W., Van Herreweghe, F., & Vanden Berghe, T. (2010) · Science Signaling · doi:10.1126/scisignal.3115re4 · Cited by 482
Bifidobacterium infantis35624 modulates host inflammatory processes beyond the gut
Groeger, D., O’Mahony, L., Murphy, E. F., Bourke, J. F., Dinan, T. G., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2013) · Gut Microbes · doi:10.4161/gmic.25487 · Cited by 448
“They are not employed in clinical practice but both of these cytokines have been targeted by aggressive anti-cytokine biologic agent therapy in the treatment of autoimmune diseases.(37,38) The attenuation of CRP following B.”
Background
Metadata
- Authors
- Feldmann, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2008-11-03
- Volume
- 118
- Issue
- 11
- Pages
- 3533-3536
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2019137678
- Cited by
- 158
- References
- 4
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Many cytokines are very useful therapeutic targets in disease. https://app.cochat.ai/papers/10.1172/jci37346
- The paper
- Feldmann, M. (2008). Many cytokines are very useful therapeutic targets in disease. Journal of Clinical Investigation. https://doi.org/10.1172/jci37346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.